Patient‐reported quality‐of‐life outcomes after de‐escalated chemoradiation for human papillomavirus‐positive oropharyngeal carcinoma: Findings from a phase 2 trial
Open Access
Abstract
BACKGROUND: The current study represents a subset analysis of quality‐of‐life (QOL) outcomes among patients treated on a phase 2 trial of de‐escalated chemoradiation for human papillomavirus (HPV)‐associated oropharyngeal cancer.METHODS: Eligibility included newly diagnosed, (American Joint Committee on Cancer, 7th edition) stage III or IV oropharyngeal squamous cell carcinoma, p16 positivity, age ≥ 18 years, and a Zubrod performance status of 0 to 1. Treatment was induction paclitaxel at a dose of 175 mg/m2 and carboplatin at an area under the curve of 6 for 2 cycles followed by response‐adapted, dose‐reduced radiation of 54 Gy or 60 Gy with weekly concurrent paclitaxel at a dose of 30 mg/m2. The University of Washington Quality of Life (UW‐QOL) and the Functional Assessment of Cancer Therapy‐Head and Neck questionnaires were used to assess patient‐reported QOL as a secondary endpoint.RESULTS: A total of 45 patients were registered, 40 of whom completed QOL surveys and were evaluable. Nadirs for overall UW‐QOL and Functional Assessment of Cancer Therapy‐Head and Neck scores were reached at 4 weeks after treatment but returned to baseline at 3 months. Nearly all functional indices returned to baseline levels by 6 to 9 months. The mean overall UW‐QOL score was 71.6 at baseline compared with 70.8, 73.0, 83.3, and 81.1, respectively, at 3 months, 6 months, 1 year, and 2 years after therapy. The percentage of patients rating their overall QOL as “very good” or “outstanding” at 6 months, 1 year, and 2 years using the UW‐QOL was 50%, 77%, and 84%, respectively.CONCLUSIONS: This de‐escalation regimen achieved QOL outcomes that were favorable compared with historical controls. These results serve as powerful evidence that ongoing de‐escalation efforts lead to tangible gains in function and QOL. Cancer 2018;124:521‐9. © 2017 American Cancer Society.Keywords
Funding Information
- University of California (P30CA093373-11)
This publication has 25 references indexed in Scilit:
- Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2017
- Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck CancerJAMA Otolaryngology–Head & Neck Surgery, 2016
- Intensity-Modulated Radiotherapy is Associated With Improved Global Quality of Life Among Long-term Survivors of Head-and-Neck CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Radiotherapy Dose–Volume Effects on Salivary Gland FunctionInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Dosimetric Factors Associated With Long-Term Dysphagia After Definitive Radiotherapy for Squamous Cell Carcinoma of the Head and NeckInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Clinical-dosimetric analysis of measures of dysphagia including gastrostomy-tube dependence among head and neck cancer patients treated definitively by intensity-modulated radiotherapy with concurrent chemotherapyRadiation Oncology, 2009
- Radiation Response in Two HPV-Infected Head-and-Neck Cancer Cell Lines in Comparison to a Non–HPV-Infected Cell Line and Relationship to Signaling Through AKTInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Prospective Study of Psychosocial Distress Among Patients Undergoing Radiotherapy for Head and Neck CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical TrialJNCI: Journal of the National Cancer Institute, 2008
- Assessment of quality of life in head and neck cancer patientsHead & Neck, 1993